Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 108

1.

Evaluation of age-related differences in the immunogenicity of a G9 H9N2 influenza vaccine.

Atmar RL, Keitel WA, Quarles JM, Cate TR, Patel SM, Nino D, Wells J, Arden N, Guo K, Hill H, Couch RB.

Vaccine. 2011 Oct 19;29(45):8066-72. doi: 10.1016/j.vaccine.2011.08.044. Epub 2011 Aug 22.

2.

Comparison of the immunogenicity and safety of a split-virion, inactivated, trivalent influenza vaccine (Fluzone®) administered by intradermal and intramuscular route in healthy adults.

Frenck RW Jr, Belshe R, Brady RC, Winokur PL, Campbell JD, Treanor J, Hay CM, Dekker CL, Walter EB Jr, Cate TR, Edwards KM, Hill H, Wolff M, Leduc T, Tornieporth N.

Vaccine. 2011 Aug 5;29(34):5666-74. doi: 10.1016/j.vaccine.2011.06.010. Epub 2011 Jun 23.

3.

A high dosage influenza vaccine induced significantly more neuraminidase antibody than standard vaccine among elderly subjects.

Cate TR, Rayford Y, Niño D, Winokur P, Brady R, Belshe R, Chen W, Atmar RL, Couch RB.

Vaccine. 2010 Feb 25;28(9):2076-9. doi: 10.1016/j.vaccine.2009.12.041. Epub 2009 Dec 29.

4.

A phase I evaluation of inactivated influenza A/H5N1 vaccine administered by the intradermal or the intramuscular route.

Patel SM, Atmar RL, El Sahly HM, Cate TR, Keitel WA.

Vaccine. 2010 Apr 9;28(17):3025-9. doi: 10.1016/j.vaccine.2009.10.152. Epub 2009 Nov 18.

5.

Contrasting effects of type I interferon as a mucosal adjuvant for influenza vaccine in mice and humans.

Couch RB, Atmar RL, Cate TR, Quarles JM, Keitel WA, Arden NH, Wells J, Niño D, Wyde PR.

Vaccine. 2009 Aug 27;27(39):5344-8. doi: 10.1016/j.vaccine.2009.06.084. Epub 2009 Jul 14.

6.

Increasing doses of an inactivated influenza A/H1N1 vaccine induce increasing levels of cross-reacting antibody to subsequent, antigenically different, variants.

Keitel WA, Atmar RL, Nino D, Cate TR, Couch RB.

J Infect Dis. 2008 Oct 1;198(7):1016-8. doi: 10.1086/591465.

PMID:
18729777
7.

Immunogenicity, safety and consistency of new trivalent inactivated influenza vaccine.

Talbot HK, Keitel W, Cate TR, Treanor J, Campbell J, Brady RC, Graham I, Dekker CL, Ho D, Winokur P, Walter E, Bennet J, Formica N, Hartel G, Skeljo M, Edwards KM.

Vaccine. 2008 Jul 29;26(32):4057-61. doi: 10.1016/j.vaccine.2008.05.024. Epub 2008 Jun 2.

8.

Safety and immunogenicity of a high dosage trivalent influenza vaccine among elderly subjects.

Couch RB, Winokur P, Brady R, Belshe R, Chen WH, Cate TR, Sigurdardottir B, Hoeper A, Graham IL, Edelman R, He F, Nino D, Capellan J, Ruben FL.

Vaccine. 2007 Nov 1;25(44):7656-63. Epub 2007 Sep 14.

9.

A dose-response evaluation of inactivated influenza vaccine given intranasally and intramuscularly to healthy young adults.

Atmar RL, Keitel WA, Cate TR, Munoz FM, Ruben F, Couch RB.

Vaccine. 2007 Jul 20;25(29):5367-73. Epub 2007 May 22.

10.

Safety and immunogenicity of nonadjuvanted and MF59-adjuvanted influenza A/H9N2 vaccine preparations.

Atmar RL, Keitel WA, Patel SM, Katz JM, She D, El Sahly H, Pompey J, Cate TR, Couch RB.

Clin Infect Dis. 2006 Nov 1;43(9):1135-42. Epub 2006 Sep 25.

PMID:
17029131
11.

Safety of high doses of influenza vaccine and effect on antibody responses in elderly persons.

Keitel WA, Atmar RL, Cate TR, Petersen NJ, Greenberg SB, Ruben F, Couch RB.

Arch Intern Med. 2006 May 22;166(10):1121-7.

PMID:
16717175
12.

Dose-related safety and immunogenicity of a trivalent baculovirus-expressed influenza-virus hemagglutinin vaccine in elderly adults.

Treanor JJ, Schiff GM, Couch RB, Cate TR, Brady RC, Hay CM, Wolff M, She D, Cox MM.

J Infect Dis. 2006 May 1;193(9):1223-8. Epub 2006 Mar 28.

PMID:
16586358
13.

Serum immunoglobulin G response to candidate vaccine antigens during experimental human pneumococcal colonization.

McCool TL, Cate TR, Tuomanen EI, Adrian P, Mitchell TJ, Weiser JN.

Infect Immun. 2003 Oct;71(10):5724-32.

14.

The immune response to pneumococcal proteins during experimental human carriage.

McCool TL, Cate TR, Moy G, Weiser JN.

J Exp Med. 2002 Feb 4;195(3):359-65.

15.

Immunization against influenza: comparison of various topical and parenteral regimens containing inactivated and/or live attenuated vaccines in healthy adults.

Keitel WA, Cate TR, Nino D, Huggins LL, Six HR, Quarles JM, Couch RB.

J Infect Dis. 2001 Jan 15;183(2):329-332. Epub 2000 Dec 8.

PMID:
11110645
16.

Human immune response to streptococcal inhibitor of complement, a serotype M1 group A Streptococcus extracellular protein involved in epidemics.

Hoe NP, Kordari P, Cole R, Liu M, Palzkill T, Huang W, McLellan D, Adams GJ, Hu M, Vuopio-Varkila J, Cate TR, Pichichero ME, Edwards KM, Eskola J, Low DE, Musser JM.

J Infect Dis. 2000 Nov;182(5):1425-36. Epub 2000 Oct 3.

PMID:
11015234
18.

Impact of influenza and other community-acquired viruses.

Cate TR.

Semin Respir Infect. 1998 Mar;13(1):17-23. Review.

PMID:
9543472
19.

Effects of requiring prior authorization for selected antimicrobials: expenditures, susceptibilities, and clinical outcomes.

White AC Jr, Atmar RL, Wilson J, Cate TR, Stager CE, Greenberg SB.

Clin Infect Dis. 1997 Aug;25(2):230-9.

PMID:
9332517
20.

Improvement of inactivated influenza virus vaccines.

Couch RB, Keitel WA, Cate TR.

J Infect Dis. 1997 Aug;176 Suppl 1:S38-44. Review.

PMID:
9240693
21.

Efficacy of repeated annual immunization with inactivated influenza virus vaccines over a five year period.

Keitel WA, Cate TR, Couch RB, Huggins LL, Hess KR.

Vaccine. 1997 Jul;15(10):1114-22.

PMID:
9269055
22.
23.

Increasing doses of purified influenza virus hemagglutinin and subvirion vaccines enhance antibody responses in the elderly.

Keitel WA, Cate TR, Atmar RL, Turner CS, Nino D, Dukes CM, Six HR, Couch RB.

Clin Diagn Lab Immunol. 1996 Sep;3(5):507-10.

24.

Tuberculous meningitis among adults with and without HIV infection. Experience in an urban public hospital.

Yechoor VK, Shandera WX, Rodriguez P, Cate TR.

Arch Intern Med. 1996 Aug 12-26;156(15):1710-6. Erratum in: Arch Intern Med 1997 May 12;157(9):1022.

PMID:
8694670
25.

Human immunodeficiency virus-associated atypical mycobacterial skeletal infections.

Hirsch R, Miller SM, Kazi S, Cate TR, Reveille JD.

Semin Arthritis Rheum. 1996 Apr;25(5):347-56. Review. Erratum in: Semin Arthritis Rheum 1996 Aug;26(1):504.

PMID:
8778990
26.

Enforcing antimicrobial restrictions.

White AC Jr, Atmar RL, Cate TR, Greenberg SR.

Am J Health Syst Pharm. 1996 Apr 1;53(7):796-7. No abstract available.

PMID:
8697031
27.

Purified influenza A virus N2 neuraminidase vaccine is immunogenic and non-toxic in humans.

Kilbourne ED, Couch RB, Kasel JA, Keitel WA, Cate TR, Quarles JH, Grajower B, Pokorny BA, Johansson BE.

Vaccine. 1995 Dec;13(18):1799-803.

PMID:
8701596
28.

Comparison of trivalent cold-adapted recombinant (CR) influenza virus vaccine with monovalent CR vaccines in healthy unselected adults.

Atmar RL, Keitel WA, Cate TR, Quarles JM, Couch RB.

J Infect Dis. 1995 Jul;172(1):253-7.

PMID:
7797925
29.

Influenza A subtype cross-protection after immunization of outbred mice with a purified chimeric NS1/HA2 influenza virus protein.

Mbawuike IN, Dillion SB, Demuth SG, Jones CS, Cate TR, Couch RB.

Vaccine. 1994 Nov;12(14):1340-8.

PMID:
7856302
30.

High doses of purified influenza A virus hemagglutinin significantly augment serum and nasal secretion antibody responses in healthy young adults.

Keitel WA, Couch RB, Cate TR, Hess KR, Baxter B, Quarles JM, Atmar RL, Six HR.

J Clin Microbiol. 1994 Oct;32(10):2468-73.

31.

Developing and implementing guidelines to promote appropriate use of fluconazole therapy in an AIDS clinic.

Anassi EO, Egbunike IG, Akpaffiong MJ, Ike EN, Cate TR.

Hosp Pharm. 1994 Jun;29(6):576-8, 581-2, 585-6.

PMID:
10134178
32.

Concurrent ceftazidime DUE with clinical pharmacy intervention.

Okpara AU, Van Duyn OM, Cate TR, Cheung LK, Galley MA.

Hosp Formul. 1994 May;29(5):392-4, 399, 402-4.

PMID:
10133902
33.

Variability in infectivity of cold-adapted recombinant influenza virus vaccines in humans.

Keitel WA, Couch RB, Cate TR, Maassab HF.

J Infect Dis. 1994 Feb;169(2):477. No abstract available.

PMID:
8106789
34.

In situ hybridization and immunohistochemical analysis of cytomegalovirus-associated ileal perforation.

Genta RM, Bleyzer I, Cate TR, Tandon AK, Yoffe B.

Gastroenterology. 1993 Jun;104(6):1822-7.

PMID:
8388840
35.

Trivalent attenuated cold-adapted influenza virus vaccine: reduced viral shedding and serum antibody responses in susceptible adults.

Keitel WA, Couch RB, Quarles JM, Cate TR, Baxter B, Maassab HF.

J Infect Dis. 1993 Feb;167(2):305-11.

PMID:
8421165
36.

Response of latent syphilis or neurosyphilis to ceftriaxone therapy in persons infected with human immunodeficiency virus.

Dowell ME, Ross PG, Musher DM, Cate TR, Baughn RE.

Am J Med. 1992 Nov;93(5):481-8.

PMID:
1442850
37.

Nosocomial influenza in a general hospital for indigent patients.

Glezen WP, Falcao O, Cate TR, Mintz AA.

Can J Infect Control. 1991 Autumn;6(3):65-7.

PMID:
1824284
38.

Prevention of influenza and pneumonia.

Mostow SR, Cate TR, Ruben FL.

Am Rev Respir Dis. 1990 Aug;142(2):487-8. No abstract available.

PMID:
2382913
40.
41.

Prevention of severe lower respiratory tract infections.

Cate TR.

Semin Respir Infect. 1989 Dec;4(4):243-4. No abstract available.

PMID:
2626599
42.

Efficacy of sequential annual vaccination with inactivated influenza virus vaccine.

Keitel WA, Cate TR, Couch RB.

Am J Epidemiol. 1988 Feb;127(2):353-64.

PMID:
3337087
43.

Clinical manifestations and consequences of influenza.

Cate TR.

Am J Med. 1987 Jun 19;82(6A):15-9.

PMID:
3591813
44.

Influenza pneumonia.

Ruben FL, Cate TR.

Semin Respir Infect. 1987 Jun;2(2):122-9. Review.

PMID:
3321270
45.

Influenza: its control in persons and populations.

Couch RB, Kasel JA, Glezen WP, Cate TR, Six HR, Taber LH, Frank AL, Greenberg SB, Zahradnik JM, Keitel WA.

J Infect Dis. 1986 Mar;153(3):431-40. No abstract available.

PMID:
3950437
47.

Managing influenza in older patients.

Couch RB, Cate TR.

Geriatrics. 1983 Sep;38(9):61-3, 67, 71-4. No abstract available.

PMID:
6884776
48.

Reactogenicity, immunogenicity, and antibody persistence in adults given inactivated influenza virus vaccines - 1978.

Cate TR, Couch RB, Parker D, Baxter B.

Rev Infect Dis. 1983 Jul-Aug;5(4):737-47.

PMID:
6622888
50.

Supplemental Content

Support Center